These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34124183)

  • 21. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Escherichia coli and Proteus mirabilis inhibit the perinuclear but not the circulating antineutrophil cytoplasmic antibody reaction.
    Yang P; Danielsson D; Järnerot G
    Scand J Gastroenterol; 1998 May; 33(5):529-34. PubMed ID: 9648994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complexes between proteinase 3, alpha 1-antitrypsin and proteinase 3 anti-neutrophil cytoplasm autoantibodies: a comparison between alpha 1-antitrypsin PiZ allele carriers and non-carriers with Wegener's granulomatosis.
    Baslund B; Szpirt W; Eriksson S; Elzouki AN; Wiik A; Wieslander J; Petersen J
    Eur J Clin Invest; 1996 Sep; 26(9):786-92. PubMed ID: 8889441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Golimumab for moderately to severely active ulcerative colitis.
    Kedia S; Ahuja V; Makharia GK
    Expert Rev Clin Pharmacol; 2016 Oct; 9(10):1273-82. PubMed ID: 27498886
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Post-Induction Adalimumab Concentration is Associated with Short-Term Mucosal Healing in Patients with Ulcerative Colitis.
    Papamichael K; Baert F; Tops S; Assche GV; Rutgeerts P; Vermeire S; Gils A; Ferrante M
    J Crohns Colitis; 2017 Jan; 11(1):53-59. PubMed ID: 27402915
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis.
    Fernández-Blanco JI; Fernández-Díaz G; Cara C; Vera MI; Olivares D; Taxonera C
    Dig Dis Sci; 2018 Mar; 63(3):731-737. PubMed ID: 29372480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic heterogeneity within ulcerative colitis determined by an interleukin-1 receptor antagonist gene polymorphism and antineutrophil cytoplasmic antibodies.
    Papo M; Quer JC; Gutierrez C; Broch M; Casellas F; Pastor RM; Olona M; Richart C
    Eur J Gastroenterol Hepatol; 1999 Apr; 11(4):413-20. PubMed ID: 10321759
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis.
    Taxonera C; Rodríguez C; Bertoletti F; Menchén L; Arribas J; Sierra M; Arias L; Martínez-Montiel P; Juan A; Iglesias E; Algaba A; Manceñido N; Rivero M; Barreiro-de Acosta M; López-Serrano P; Argüelles-Arias F; Gutierrez A; Busquets D; Gisbert JP; Olivares D; Calvo M; Alba C;
    Inflamm Bowel Dis; 2017 Aug; 23(8):1394-1402. PubMed ID: 28671873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis.
    Elzouki AN; Eriksson S; Löfberg R; Nässberger L; Wieslander J; Lindgren S
    Inflamm Bowel Dis; 1999 Nov; 5(4):246-52. PubMed ID: 10579117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical significance of positive anti-neutrophil cytoplasmic antibodies without evidence of anti-neutrophil cytoplasmic antibodies-associated vasculitis.
    Bornstein G; Ben-Zvi I; Furie N; Grossman C
    Int J Rheum Dis; 2019 May; 22(5):940-945. PubMed ID: 30729688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Golimumab for the treatment of ulcerative colitis.
    Löwenberg M; de Boer NKh; Hoentjen F
    Clin Exp Gastroenterol; 2014; 7():53-9. PubMed ID: 24648749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study.
    Yamamoto T; Shimoyama T; Umegae S; Matsumoto K
    Aliment Pharmacol Ther; 2016 Mar; 43(6):705-16. PubMed ID: 26762838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
    Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
    Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
    [No Abstract]   [Full Text] [Related]  

  • 36. Systematic review with network meta-analysis: the efficacy of anti-tumour necrosis factor-alpha agents for the treatment of ulcerative colitis.
    Stidham RW; Lee TC; Higgins PD; Deshpande AR; Sussman DA; Singal AG; Elmunzer BJ; Saini SD; Vijan S; Waljee AK
    Aliment Pharmacol Ther; 2014 Apr; 39(7):660-71. PubMed ID: 24506179
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.
    Barber GE; Yajnik V; Khalili H; Giallourakis C; Garber J; Xavier R; Ananthakrishnan AN
    Am J Gastroenterol; 2016 Dec; 111(12):1816-1822. PubMed ID: 27596696
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alpha 1-antitrypsin deficiency and anti-proteinase 3 antibodies in anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis.
    Savige JA; Chang L; Cook L; Burdon J; Daskalakis M; Doery J
    Clin Exp Immunol; 1995 May; 100(2):194-7. PubMed ID: 7743654
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction between CD177 and platelet endothelial cell adhesion molecule-1 downregulates membrane-bound proteinase-3 (PR3) expression on neutrophils and attenuates neutrophil activation induced by PR3-ANCA.
    Deng H; Hu N; Wang C; Chen M; Zhao MH
    Arthritis Res Ther; 2018 Sep; 20(1):213. PubMed ID: 30236159
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis.
    Moxey J; Huq M; Proudman S; Sahhar J; Ngian GS; Walker J; Strickland G; Wilson M; Ross L; Major G; Roddy J; Stevens W; Nikpour M
    Arthritis Res Ther; 2019 Feb; 21(1):57. PubMed ID: 30764870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.